CANNAPHARMARX, INC.
CPMD evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for CPMD—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Mar 31, 2026.
Tracking 1 pipeline candidate for CANNAPHARMARX, INC..
Run CANNAPHARMARX, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available CANNAPHARMARX, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 3 of 6 signals · derived from public data
3.4 months
OCF -$244K · Net income -$382K
No tracked pipeline phase
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Financials
Governance
Frequently asked questions
Who is the CEO of CANNAPHARMARX, INC.?
Mr. Constantine Nkafu is the chief executive officer of CANNAPHARMARX, INC. (CPMD).
Where is CANNAPHARMARX, INC. headquartered?
CANNAPHARMARX, INC. (CPMD) is headquartered in Cremona, AB, Canada.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.